Idiopathic recurrent pericarditis — a paradigm shift?
https://doi.org/10.15829/1560-4071-2019-11-155-163
Abstract
Idiopathic recurrent pericarditis (IRP) is a relatively rare inflammatory disease of the pericardium, often requiring emergency medical care, associated with a high percentage of temporary disability and significant economic costs. The review presents various points of view on the pathogenesis of recurrent pericarditis, discusses the role of autoinflammation. It touches on treatment issues based on modern data on the IRP immunopathogenesis, and considers promising areas of laboratory diagnostics.
About the Authors
V. Yu. Myachikova
Almazov National Medical Research Center
Russian Federation
Russian Federation
St. Petersburg.
V. A. Titov
Almazov National Medical Research Center
Russian Federation
Russian Federation
St. Petersburg.
A. L. Maslyanskiy
Almazov National Medical Research Center
Russian Federation
Russian Federation
St. Petersburg.
O. M. Moiseeva
Almazov National Medical Research Center
Russian Federation
Russian Federation
St. Petersburg.
References
1. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European heart journal.2015;36(42):2921-64. doi:10.1093/eurheartj/ehv318.
2. Brucato A, Imazio M, Cremer PC, et al. Recurrent pericarditis: still idiopathic? The pros and cons of a well-honoured term. Internal and Emergency Medicine. 2018;13(6):839-44. doi:10.1007/s11739-018-1907-x.
3. Brucato A, Emmi G, Cantarini L, et al. Management of idiopathic recurrent pericarditis in adults and in children: A role for IL-1 receptor antagonism. Internal and Emergency Medicine. 2018;13(4):475-89. doi:10.1007/s11739-018-1842-x.
4. Kytö V, Sipilä J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation. 2014;130(18):1601-6. doi:10.1161/CIRCULATIONAHA.114.010376.
5. Imazio M, Lazaros G, Brucato A, Gaita F. Recurrent pericarditis: new and emerging therapeutic options. Nature Reviews Cardiology. 2015;13(2):99-105. doi:10.1038/nrcardio.2015.115.
6. Woodward TE, Mccrumb FR, Carey TN, Togo Y. Viral and rickettsial causes of cardiac disease, including the coxsackie virus etiology of pericarditis and myocarditis. Annals of Internal Medicine.1960;53(6):1130-50. doi:10.7326/0003-4819-53-6-1130.
7. Pankuweit S, Stein A, Karatolios K, et al. Viral genomes in the pericardial fluid and in peri- and epicardial biopsies from a German cohort of patients with large to moderate pericardial effusions. Heart failure reviews. 2013;18(3):329-36. doi:10.1007/s10741-013-9375-x.
8. Cantarini L, Lopalco G, Selmi C, et al. Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. Autoimmunity reviews. 2015;14(2):90-7. doi:10.1016/j.autrev.2014.10.005.
9. McGonagle D, McDermott MF. A Proposed Classification of the Immunological Diseases. PLoS Medicine. 2006;3(8),e297. doi:10.1371/journal.pmed.0030297.
10. Higgs BW, Liu Z, White B, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Annals of the Rheumatic Diseases. 2011;70(11):2029-36. doi:10.1136/ard.2011.150326.
11. Maslyanskiy AL, Penin IN, Cheshuina MD, et al. Common consistent patterns of the cytokine and chemokine production in patients with diffuse connective tissue diseases, inflammatory arthropathies and atherosclerosis. Cytokines and inflammation. 2014;13(3):9-21. (In Russ.)
12. Moll M, Kuemmerle-Deschner JB. Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clinical immunology (Orlando, Fla.). 2013;147(3):242-75. doi:10.1016/j.clim.2013.04.008.
13. Caforio ALP, Adler Y, Agostini C, et al. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. European heart journal. 2017;38(35):2649-62. doi:10.1093/eurheartj/ehx321.
14. Buchmann K. Evolution of innate immunity: clues from invertebrates via fish to mammals. Front Immunol. 2014;5: 459. doi:10.3389/fimmu.2014.00459.
15. De Nardo D. Toll-like receptors: Activation, signalling and transcriptional modulation. Cytokine. 2015;74(2):181-9. doi:10.1016/j.cyto.2015.02.025.
16. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nature Reviews Immunology. 2013;13(6):397-411. doi:10.1038/nri3452.
17. Rieber N, Gavrilov A, Hofer L, et al. A functional inflammasome activation assay differentiates patients with pathogenic NLRP3 mutations and symptomatic patients with low penetrance variants. Clinical Immunology. 2015;157(1):56-64. doi:10.1016/j.clim.2015.01.003.
18. Kougkas N, Fanouriakis A, Papalopoulos I, et al. Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up. Rheumatology (Oxford, England). 2018;57(8):1494-5. doi:10.1093/rheumatology/key077.
19. García-García G, Fernández-Auzmendi V, Olgado-Ferrero F, et al. Acute Miopericarditis as the Presenting Feature of Adult-Onset Still’s Disease. Reumatología Clínica (English Edition). 2012;8(1):31-3. doi:10.1016/j.reumae.2011.03.002.
20. Myachikova VYu, Maslyansky AL, Gaydukova IZ, et al. Difficulties in diagnosis and treatment of adult-onset Still’s disease concurrent with pericardial effusion as a leading clinical manifestation. Sovremennaya revmatologia. 2016;10(1):31-6. (In Russ.)
21. Ravet N, Rouaghe S, Dode C, et al. Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Annals of the Rheumatic Diseases. 2006;65(9):1158-62. doi:10.1136/ard.2005.048611.
22. Lachmann HJ, Papa R, Gerhold K, et al. for the Paediatric Rheumatology International Trials Organisation (PRINTO), the EUROTRAPS and the Eurofever Project. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever. Annals of the Rheumatic Diseases. 2014;73:2160-7. doi:10.1136/annrheumdis-2013-204184.
23. Brucato A, Shinar Y, Brambilla G, et al. Idiopathic recurrent acute pericarditis: familial Mediterranean fever mutations and disease evolution in a large cohort of Caucasian patients. Lupus. 2005;14(9):670-4. doi:10.1191/0961203305lu2197oa.
24. Brucato A, Brambilla G, Moreo A, et al. Long-Term Outcomes in Difficult-to-Treat Patients With Recurrent Pericarditis. The American Journal of Cardiology. 2006;98(2):267-71. doi:10.1016/j.amjcard.2006.01.086.
25. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19(3):424-30.
26. Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol. 2008;22(5):773-92. doi:10.1016/j.berh.2008.08.006.
27. Cush JJ, Medsger TA, Christy WC, et al. Adult-onset still’s disease. Arthritis & Rheumatism. 1987;30(2):186-94. doi:10.1002/art.1780300209.
28. Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nature reviews. Rheumatology. 2018;14(10):603-18. doi:10.1038/s41584-018-0081-x.
29. Masliansky AL, Mazurov VI, Zotkin EG, et al. Anti-B cell therapy of autoimmune diseases. Med. Immunol. 2007;9(1):15-34. (In Russ.)
30. Maisch B, Berg PA, Kocksiek K. Clinical significance of immunopathological findings in patients with post-pericardiotomy syndrome. Relevance of antibody pattern. Clin Exp Immunol 1979;38:189e97.
31. Levy Y, Shovman O, Granit C, et al. Pericarditis following permanent pacemaker insertion. Isr Med Assoc J. 2004;6:599-602.
32. Meissner M, Sherer Y, Levy Y, et al. Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis. Rheumatol Int. 2000;19:199-201.
33. Raatikka M, Pelkonen PM, Karjalainen J, Jokinen EV. Recurrent pericarditis in children and adolescents: report of 15 cases. J Am Coll Cardiol. 2003;42:759-64.
34. Imazio M, Brucato A, Pluymaekers N, et al. Recurrent pericarditis in children and adolescents. Journal of Cardiovascular Medicin. 2016;17(9):707-12. doi:10.2459/jcm.000000000000030.
35. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. International Immunology. 2017;29(9):401-9. doi:10.1093/intimm/dxx031.
36. Leung YY. Colchicine-Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341-50. doi:10.1016/j.semarthrit.2015.06.013.
37. Xu B, Harb SC, Cremer PC. New insights into pericarditis: mechanisms of injury and therapeutic targets. Current cardiology reports. 2017;19(7):60. doi:10.1007/s11886-017-0866-6.
38. Imazio M, Brucato A, Cumetti D, et al. Corticosteroids for Recurrent pericaditis: High versus Low doses: A nonrandomized observation. Circulation. 2008;118(6):667-71 doi:10.1161/CIRCULATIONAHA.107.761064.
39. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008;64:753-67.
40. Vianello F, Cinetto F, CavraroM, et al. Azathioprine in isolated recurrent pericarditis: a singlecentre experience. Int J Cardiol. 2011;147:477-8. doi:10.1016/j.ijcard.2011.01.027.
41. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012;367:2015-25. doi:10.1056/NEJMra1009433.
42. Imazio M, Lazaros G, Picardi E, et al. Intravenous human immunoglobulins for refractory recurrent pericarditis. Journal of Cardiovascular Medicine. 2016;17(4):263-9. doi:10.2459/jcm.0000000000000260.
43. Moll M, Kuemmerle-Deschner JB. Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clinical Immunology. 2013;147(3):242-75. doi:10.1016/j.clim.2013.04.008.
44. Lopalco G, Cantarini L, Vitale A, et al. Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives. Mediators of Inflammation. 2015;2015:1-21. doi:10.1155/2015/194864.
45. Simon A, Bodar E, van der Hilst JC, et al. Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med. 2004;117:208-10.
46. So A, de Smedt T, Revaz S, Tschopp J. Research article a pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis ResTher. 2007;9:1-6. doi:10.1186/ar2143.
47. Jain S, Thongprayoon C, Espinosa RE, et al. Effectiveness and safety of anakinra for management of refractory pericarditis. Am J Cardiol. 2015;116:1277-9. doi:10.1016/j.amjcard.2015.07.047.
48. Lazaros G, Vasileiou P, Koutsianas C, et al. Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases. Ann Rheum Dis. 2014;73(12):2215-7. doi:10.1136/annrheumdis-2014-205990.
49. Brucato A, Imazio M, Gattorno M, et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence. JAMA. 2016 Nov 8;316(18):1906-12. doi:10.1001/jama.2016.15826.
Review
For citations:
Myachikova V.Yu., Titov V.A., Maslyanskiy A.L., Moiseeva O.M. Idiopathic recurrent pericarditis — a paradigm shift? Russian Journal of Cardiology. 2019;(11):155-163. (In Russ.) https://doi.org/10.15829/1560-4071-2019-11-155-163
Views:
3277
Email this article 